These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7704933)
1. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Fisher CJ; Opal SM; Lowry SF; Sadoff JC; LaBrecque JF; Donovan HC; Lookabaugh JL; Lemke J; Pribble JP; Stromatt SC Circ Shock; 1994 Sep; 44(1):1-8. PubMed ID: 7704933 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 and interleukin-1 receptor antagonist. Dinarello CA Nutrition; 1995; 11(5 Suppl):492-4. PubMed ID: 8748206 [TBL] [Abstract][Full Text] [Related]
4. The role of interleukin-1 in host responses to infectious diseases. Dinarello CA Infect Agents Dis; 1992 Oct; 1(5):227-36. PubMed ID: 1344662 [TBL] [Abstract][Full Text] [Related]
5. The interleukin-1 receptor antagonist and its delivery by gene transfer. Evans CH; Robbins PD Receptor; 1994; 4(1):9-15. PubMed ID: 8038709 [TBL] [Abstract][Full Text] [Related]
6. Protective effect of interleukin-1 receptor antagonist on oleic acid-induced lung injury. Sun D; Zhao M; Ma D; Liao S; Di C Chin Med J (Engl); 1996 Jul; 109(7):522-6. PubMed ID: 9206098 [TBL] [Abstract][Full Text] [Related]
8. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism]. Li YJ; Ding WH; Gao W; Huo Y; Hong T; Zhu RY; Ma DL Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):548-53. PubMed ID: 15144587 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140 [TBL] [Abstract][Full Text] [Related]
11. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735 [TBL] [Abstract][Full Text] [Related]
12. Plasma levels of interleukin-1 receptor antagonist (IL-1ra) and severity of illness in patients with burns. Endo S; Inada K; Yamada Y; Kasai T; Takakuwa T; Nakae H; Kamei Y; Shimamura T; Suzuki T; Taniguchi S; Yoshida M J Med; 1996; 27(1-2):57-71. PubMed ID: 8863178 [TBL] [Abstract][Full Text] [Related]
13. Causal links between brain cytokines and experimental febrile convulsions in the rat. Heida JG; Pittman QJ Epilepsia; 2005 Dec; 46(12):1906-13. PubMed ID: 16393156 [TBL] [Abstract][Full Text] [Related]
14. Effect of an interleukin-1 receptor antagonist on the hemodynamic manifestations of group B streptococcal sepsis. Vallette JD; Goldberg RN; Suguihara C; Del Moral T; Martinez O; Lin J; Thompson RC; Bancalari E Pediatr Res; 1995 Nov; 38(5):704-8. PubMed ID: 8552437 [TBL] [Abstract][Full Text] [Related]
15. Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. Oren H; Cingöz I; Duman M; Yilmaz S; Irken G Pediatr Hematol Oncol; 2005 Dec; 22(8):679-88. PubMed ID: 16251173 [TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073 [TBL] [Abstract][Full Text] [Related]
17. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Jiang Y; Genant HK; Watt I; Cobby M; Bresnihan B; Aitchison R; McCabe D Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552 [TBL] [Abstract][Full Text] [Related]
18. Influence of IL-1 receptor blockade on the human response to endotoxemia. Van Zee KJ; Coyle SM; Calvano SE; Oldenburg HS; Stiles DM; Pribble J; Catalano M; Moldawer LL; Lowry SF J Immunol; 1995 Feb; 154(3):1499-507. PubMed ID: 7822813 [TBL] [Abstract][Full Text] [Related]
19. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Kopp WC; Urba WJ; Rager HC; Alvord WG; Oppenheim JJ; Smith JW; Longo DL Clin Cancer Res; 1996 Mar; 2(3):501-6. PubMed ID: 9816196 [TBL] [Abstract][Full Text] [Related]
20. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Dayer JM Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]